Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Active, not recruiting

• Conditions: Multiple Myeloma; Myelodysplastic Syndrome; Acute Leukemia; Acute Lymphoblastic Leukemia

• Registration Number: NCT00048958
• Lead Sponsor: Alliance for Clinical Trials in Oncology

Brief Summary

Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2002-11-12
• Study First Submitted QC: 2003-01-26
• Study First Posted: 2003-01-27
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-30
• Last Update Posted: 2024-07-31
• Primary Completion: 2100-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 9000

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlate specific karyotype groups with selected molecular abnormalities as studied in CALGB leukemia protocols	Up to 10 years
To correlate specific karyotype groups with multidrug resistance data	Up to 10 years
Determine the incidence of specific less common primary as well as common secondary chromosome abnormalities in adult AML, ALL, MDS and MM	Up to 10 years
Correlate specific (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters	Up to 10 years
Correlate specific karyotype groups with response rates, response duration, survival and cure in patients treated with various induction and post-induction regimens	Up to 10 years
To correlate specific karyotype groups with epidemiologic data (toxic exposure and family history)	Up to 10 years
To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse on subsequent clinical course	up to 10 yeras
To identify new chromosome abnormalities important in leukemogenesis	Up to 10 years

Trial Locations

Locations (137)

Rebecca and John Moores UCSD Cancer Center; 🇺🇸 La Jolla, California, United States

Camino Medical Group - Treatment Center; 🇺🇸 Mountain View, California, United States

Kaiser Permanente Medical Office -Vandever Medical Office; 🇺🇸 San Diego, California, United States

Naval Medical Center - San Diego; 🇺🇸 San Diego, California, United States

UCSF Helen Diller Family Comprehensive Cancer Center; 🇺🇸 San Francisco, California, United States

Tunnell Cancer Center at Beebe Medical Center; 🇺🇸 Lewes, Delaware, United States

CCOP - Christiana Care Health Services; 🇺🇸 Newark, Delaware, United States

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center; 🇺🇸 Washington, District of Columbia, United States

Washington Cancer Institute at Washington Hospital Center; 🇺🇸 Washington, District of Columbia, United States

Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital; 🇺🇸 Fort Lauderdale, Florida, United States

Scroll for more (127 remaining)